Brief: Newron Pharmaceuticals FY Net Loss Widens To EUR 15.04 Million

Newron Pharmaceuticals SpA

05/03/2019 06:08

March 5 (Reuters) - Newron Pharmaceuticals SpA  NWRN.S :
    * FY TOTAL REVENUES DECREASED TO EUR 4.0 MILLION FROM EUR
13.4
MILLION (2017)
    * FY CASH USED IN OPERATIONS INCREASED TO EUR 16.1 MILLION
(2017:
EUR 8.4 MILLION)
    * FY NET LOSS 15.035 MILLION EUR VERSUS LOSS 5.282 MILLION
EUR
YEAR AGO
    * EXPECTING THE RESULTS FROM OUR STARS PHASE III STUDY WITH
SARIZOTAN IN Q4 2019
    * EXPECTS ADDITIONAL APPROVALS AND LAUNCHES OF
XADAGO®/SAFINAMIDE
DURING 2019

Source text for Eikon:  ID:nTENcmb19a 
Further company coverage:  NWRN.S 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))